About: Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID‐19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID‐19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID‐19 patients
Creator	Ding, Hong Huang, Weishan Deng, Wenjun Ye, \| Yin, Shanye Ding, Lingling
Source	Medline; PMC
abstract	SARS‐CoV‐2 is highly infectious, and infection by this virus results in COVID‐19, manifesting predominantly symptoms in the lower respiratory system. Detection of viral genomic materials by RT‐PCR is the gold standard for diagnosis. Suspected COVID‐19 patients who had a documented history of exposure and exhibited symptoms, but did not have positive PCR test results, were generally self‐quarantined with prescriptions aiming to help attenuate their symptoms. These prescriptions are however neither specific nor highly effective for COVID‐19 treatment. Given the rapidly growing pandemic and the overwhelmed medical system, the number of self‐quarantined patients is increasing. There is an urgent need of alternative medicine to help patients relieve symptoms during self‐quarantine, and to potentially help increase their chances of survival and recovery from the infection. We report here a case of severe COVID‐19 that never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery. This patient was self‐quarantined and received diammonium glycyrrhizinate (DG), a steroid‐like molecule, in combination with vitamin C as alternative medicine. This patient went through severe COVID‐19 but eventually recovered upon the implementation of this treatment regimen, suggesting potential therapeutic effects of DG as alternative medicine to help relieve COVID‐19 symptoms.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1002/jmv.26064
bibo:pmid	32458502
has license	no-cc
sha1sum (hex)	e5bdb4069e94e831527dd440c77f6b9995e7c098
schema:url	https://doi.org/10.1002/jmv.26064
resource representing a document's title	Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID‐19 patients
has PubMed Central identifier	PMC7283756
has PubMed identifier	32458502
schema:publication	J Med Virol
resource representing a document's body	covid:e5bdb4069e94e831527dd440c77f6b9995e7c098#body_text
is schema:about of	named entity 'viral' named entity 'highly' named entity 'TEST RESULTS' named entity 'INFECTIOUS' named entity 'SUSPECTED' named entity 'COVID-19' named entity 'INFECTION' named entity 'symptoms' named entity 'materials' named entity 'PCR' named entity 'COVID-19' named entity 'symptoms' named entity 'documented' named entity 'RT-PCR' named entity 'COVID-19' named entity 'rat' named entity 'COVID' named entity 'Chinese traditional medicine' named entity 'COVID' named entity 'IL-6' named entity 'follow-up' named entity 'chlamydia' named entity 'follow-up' named entity 'Wuhan' named entity 'corticosteroid' named entity 'chemical structure' named entity 'quarantine' named entity 'PCR test' named entity 'pathogens' named entity 'upper respiratory' named entity 'adenovirus' named entity 'colitis' named entity 'alternative medicine' named entity 'COVID-19' named entity 'glycyrrhetinic acid' named entity 'pharmacological' named entity 'viral pneumonia' named entity 'influenza' named entity 'tested positive' named entity 'China' named entity 'treatment options' named entity 'corticosteroid' named entity 'glycyrrhizic acid' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'IL-10' named entity 'SARS-CoV' named entity 'Immunopathology' named entity 'neurotoxicity' named entity 'COVID-19' named entity 'IgM antibodies' named entity 'polymerase chain reaction (PCR) test' named entity 'COVID' named entity 'antiinflammatory' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'PCR testing' named entity 'COVID-19' named entity 'anti-inflammatory' named entity 'COVID' named entity 'China' named entity 'anti-inflammatory drug' named entity 'steroid' named entity 'severe pneumonia' named entity 'antiinflammatory' named entity 'viral pneumonia' named entity 'PCR test' named entity 'immunopathology' named entity 'antiviral activity' named entity 'self-quarantine' named entity 'kidney' named entity 'alternative medicine' named entity 'cytokine storm' named entity 'broad spectrum' named entity 'COVID-19' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software